Scholarlink

<p>Bladder cancer remains challenging to manage due to its high recurrence rate and the development of drug resistance. To address the poor solubility and limited bioavailability of artemisinin (Art), a dextran-modified zinc-based metal–organic framework (Dex@Zn-CP1@Art) was constructed as a multifunctional nanozyme platform. The dextran coating improved the biocompatibility and colloidal stability of Zn-CP1 while preserving its intrinsic catalytic activity. Dex@Zn-CP1@Art exhibited peroxidase-, catalase-, and oxidase-like activities, enabling catalytic decomposition of H<sub>2</sub>O<sub>2</sub> to generate reactive oxygen species and singlet oxygen, thereby enhancing oxidative stress under in vitro conditions. Cell-based studies demonstrated that Dex@Zn-CP1@Art reduced T24 bladder cancer cell migration and decreased MMP-9 expression compared with free artemisinin. Although limited to in vitro evaluation, these findings suggest that Dex@Zn-CP1@Art represents a promising nanozyme-based platform that integrates catalytic nanotherapy with phytochemical chemotherapy and warrants further investigation for bladder cancer–related applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Artemisinin-Loaded pH-Responsive Zn-MOF Nanozyme for Ferroptosis-Enhanced Catalytic Therapy of Bladder Cancer via MMP-9 Pathway Modulation

  • 期刊论文

  • 发表日期：

    2026年2月25日

查看全文
  • Rong Qiu,
  • Yu Chen,
  • Guoli Zuo,
  • Shengcai He,
  • Zhidan Li,
  • Jin Chen,
  • Xingzhi Tang,
  • Lize Su,
  • Jun Wu,
  • Minyu Huang

摘要

Bladder cancer remains challenging to manage due to its high recurrence rate and the development of drug resistance. To address the poor solubility and limited bioavailability of artemisinin (Art), a dextran-modified zinc-based metal–organic framework (Dex@Zn-CP1@Art) was constructed as a multifunctional nanozyme platform. The dextran coating improved the biocompatibility and colloidal stability of Zn-CP1 while preserving its intrinsic catalytic activity. Dex@Zn-CP1@Art exhibited peroxidase-, catalase-, and oxidase-like activities, enabling catalytic decomposition of H2O2 to generate reactive oxygen species and singlet oxygen, thereby enhancing oxidative stress under in vitro conditions. Cell-based studies demonstrated that Dex@Zn-CP1@Art reduced T24 bladder cancer cell migration and decreased MMP-9 expression compared with free artemisinin. Although limited to in vitro evaluation, these findings suggest that Dex@Zn-CP1@Art represents a promising nanozyme-based platform that integrates catalytic nanotherapy with phytochemical chemotherapy and warrants further investigation for bladder cancer–related applications.